^
    6d
    Prospective Cohort Study on the Efficacy and Safety of Sequential TIPS-TACE/HAIC Combined or Not Combined with Donafenib and Tislelizumab in the Treatment of BCLC Stage C Hepatocellular Carcinoma Patients with Concomitant Portal Hypertension (ChiCTR2600116845)
    P=N/A, N=96, Not yet recruiting, Beijing Youan Hospital, Capital Medical University; Beijing Youan Hospital, Capital Medical University
    New trial
    |
    Tevimbra (tislelizumab-jsgr) • Zepsun (donafenib)
    6d
    Pharmacokinetics and Individualized Dose Optimization of Donafenib in Hepatocellular Carcinoma Patients after Transjugular Intrahepatic Portosystemic Shunt (TIPS) (ChiCTR2500115846)
    P=N/A, N=20, Not yet recruiting, Beijing Youan Hospital, Capital Medical University; Beijing Youan Hospital, Capital Medical University
    New trial
    |
    Zepsun (donafenib)
    6d
    Donafenib monotherapy or combined with PD-1/L1 inhibitors or transcatheter arterial chemoembolization as adjuvant therapy in hepatocellular carcinoma patients with high-risk recurrence after radical resection, a multi-cohort clinical study. (ChiCTR2500112389)
    P=N/A, N=90, Recruiting, The First Affiliated Hospital of Harbin Medical University; The First Affiliated Hospital of Harbin Medical University
    New trial
    |
    AFP (Alpha-fetoprotein)
    |
    Zepsun (donafenib)
    6d
    Exploratory Clinical Study of TACE Combined with Iparomlimab and Tuvonralimab and Donafenib in Conversion Therapy for Unresectable Locally Advanced and Advanced Hepatocellular Carcinoma (ChiCTR2500112149)
    P=N/A, N=42, Not yet recruiting, The First Affiliated Hospital of University of science and technology of China; The First Affiliated Hospital of University of science and technology
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab) • Zepsun (donafenib) • iparomlimab (QL1604)
    6d
    A phase Ⅱ, single-arm, exploratory study of GEMOX regimen combined with tislelizumab and donafenib in the perioperative treatment of potentially resectable intrahepatic cholangiocarcinoma with high risk of recurrence (ChiCTR2500112067)
    P2, N=20, Not yet recruiting, Hunan Provincial People's Hospital; Hunan Provincial People's Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • Zepsun (donafenib)
    14d
    Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer (clinicaltrials.gov)
    P2, N=56, Not yet recruiting, Eastern Hepatobiliary Surgery Hospital
    New P2 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • Tyvyt (sintilimab) • AiTan (rivoceranib) • Zepsun (donafenib)
    17d
    A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=94, Not yet recruiting, Eastern Hepatobiliary Surgery Hospital
    New P2 trial
    |
    Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Zepsun (donafenib)
    17d
    FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Puyouheng (pucotenlimab) • Zepsun (donafenib)
    23d
    GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma (clinicaltrials.gov)
    P2, N=93, Recruiting, Fudan University | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial primary completion date
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • oxaliplatin • Zepsun (donafenib)
    1m
    CHANCE 2203: HAIC Combined With Donafenib and Sintilimab for Unresectable ICC (clinicaltrials.gov)
    P2, N=25, Completed, Zhongda Hospital | Recruiting --> Completed | Trial completion date: Jul 2023 --> Oct 2025 | Trial primary completion date: Jun 2023 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • oxaliplatin • Zepsun (donafenib)
    1m
    LncRNA ZFAS1 in hepatocellular carcinoma: A systematic review of molecular mechanisms and clinical translation. (PubMed, Noncoding RNA Res)
    Clinically, plasma ZFAS1 demonstrates enhanced diagnostic utility when combined with alpha-fetoprotein (AUC = 0.891), while therapeutic targeting of ZFAS1-mediated PI3K-AKT and PERK/ATF4 pathways shows promise in overcoming sorafenib/donafenib resistance. Current translational challenges include ZFAS1 isoform heterogeneity, suboptimal liquid biopsy sensitivity, and dynamic TME interactions. Future directions should employ multi-omics integration (spatial transcriptomics/single-cell sequencing) coupled with AI-driven network modeling to systematically decode ZFAS1's regulatory architecture, ultimately enabling precision theranostic strategies for HCC management.
    Review • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • AFP (Alpha-fetoprotein) • ATF4 (Activating Transcription Factor 4) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2) • MIR150 (MicroRNA 150) • MIR193A (MicroRNA 193a) • MMP14 (Matrix Metallopeptidase 14) • ZFAS1 (ZNFX1 Antisense RNA 1)
    |
    sorafenib • Zepsun (donafenib)
    2ms
    Neo-TACE: Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. (clinicaltrials.gov)
    P2/3, N=18, Terminated, Peking University | N=156 --> 18 | Trial completion date: Dec 2027 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Oct 2025; Difficult to enroll participants
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Zepsun (donafenib)